1-7 of 7
Sasanka M. Handunnetti
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Venetoclax-rituximab is active in patients with BTKi-exposed CLL, but durable treatment-free remissions are uncommon

Thomas E. Lew, Rory Bennett, Victor S. Lin, Ashley Whitechurch, Sasanka M. Handunnetti, Paula Marlton, Yandong Shen, Stephen P. Mulligan, Joshua Casan, Piers Blombery, Constantine S. Tam, Andrew W. Roberts, John F. Seymour, Philip A. Thompson, Mary A. Anderson
Journal: Blood Advances
Blood Adv (2024) 8 (6): 1439–1443.
https://doi.org/10.1182/bloodadvances.2023011327
Published: 2024
Includes: Supplemental data
Journal Articles

Enrichment of BTK Leu528Trp mutations in patients with CLL on zanubrutinib: potential for pirtobrutinib cross-resistance

Piers Blombery, Ella R. Thompson, Thomas E. Lew, Ing Soo Tiong, Rory Bennett, Chan Y. Cheah, Katharine Louise Lewis, Sasanka M. Handunnetti, Chloe Pek Sang Tang, Andrew Roberts, John F. Seymour, Constantine S. Tam
Journal: Blood Advances
Blood Adv (2022) 6 (20): 5589–5592.
https://doi.org/10.1182/bloodadvances.2022008325
Published: 2022
Includes: Supplemental data
Journal Articles

Single-cell sequencing demonstrates complex resistance landscape in CLL and MCL treated with BTK and BCL2 inhibitors

Ella R. Thompson, Tamia Nguyen, Yamuna Kankanige, John F. Markham, Mary Ann Anderson, Sasanka M. Handunnetti, Rachel Thijssen, Paul Sung-Hao Yeh, Constantine S. Tam, John F. Seymour, Andrew W. Roberts, David A. Westerman, Piers Blombery
Journal: Blood Advances
Blood Adv (2022) 6 (2): 503–508.
https://doi.org/10.1182/bloodadvances.2021006211
Published: 2022
Includes: Supplemental data
Journal Articles

Outcomes of patients with CLL sequentially resistant to both BCL2 and BTK inhibition

Clinical Trials & Observations
Thomas E. Lew, Victor S. Lin, Edward R. Cliff, Piers Blombery, Ella R. Thompson, Sasanka M. Handunnetti, David A. Westerman, Bryone J. Kuss, Constantine S. Tam, David C. S. Huang, John F. Seymour, Andrew W. Roberts, Mary Ann Anderson
Journal: Blood Advances
Blood Adv (2021) 5 (20): 4054–4058.
https://doi.org/10.1182/bloodadvances.2021005083
Published: 2021
Includes: Supplemental data
Journal Articles

Immune recovery in patients with mantle cell lymphoma receiving long-term ibrutinib and venetoclax combination therapy

Clinical Trials & Observations
Joanne E. Davis, Sasanka M. Handunnetti, Mandy Ludford-Menting, Chia Sharpe, Piers Blombery, Mary Ann Anderson, Andrew W. Roberts, John F. Seymour, Constantine S. Tam, David S. Ritchie, Rachel M. Koldej
Journal: Blood Advances
Blood Adv (2020) 4 (19): 4849–4859.
https://doi.org/10.1182/bloodadvances.2020002810
Published: 2020
Includes: Supplemental data
Journal Articles

Undetectable peripheral blood MRD should be the goal of venetoclax in CLL, but attainment plateaus after 24 months

Clinical Trials & Observations
Thomas E. Lew, Mary Ann Anderson, Victor S. Lin, Sasanka M. Handunnetti, Neil A. Came, Piers Blombery, David A. Westerman, Meaghan Wall, Constantine S. Tam, Andrew W. Roberts, John F. Seymour
Journal: Blood Advances
Blood Adv (2020) 4 (1): 165–173.
https://doi.org/10.1182/bloodadvances.2019000864
Published: 2020
Includes: Supplemental data
Journal Articles

Ibrutinib, but not zanubrutinib, induces platelet receptor shedding of GPIb-IX-V complex and integrin α IIb β 3 in mice and humans

Gasim Dobie, Fahd A. Kuriri, Musab M. A. Omar, Fehaid Alanazi, Ali M. Gazwani, Chloe P. S. Tang, Daniel Man-yuen Sze, Sasanka M. Handunnetti, Constantine Tam, Denise E. Jackson
Journal: Blood Advances
Blood Adv (2019) 3 (24): 4298–4311.
https://doi.org/10.1182/bloodadvances.2019000640
Published: 2019
Includes: Supplemental data